Sign in
TerminatedPhase 3

Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

Key facts

Who runs it
Peking Union Medical College Hospital
Where
China7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
12 people enrolled
Started
14 Apr 2021
Ended
20 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rituximab
  • cyclosporine
Record updated
9 December 2025
Why it stopped
insufficient patient enrollment

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • idiopathic MN with or without diagnostic biopsy
  • Female, must be post-menopausal, sterile or have effective method of contraception
  • must be off steroid or mycophenolate mofetil for >1 month and alkylating agents for > 6 months
  • Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥3 months prior to randomization with controlled blood pressure or if patients is intolerant to ACEI/ARB
  • proteinuria ≥4g/24h using the average from two 24-hour urine samples collected within 2 weeks of each other, and decreased ≤50% from baseline
  • estimated glomerular filtration rate (eGFR) ≥40ml/min/1.73m2

Who cannot take part

  • Patients who previously achieved remission after treatment of CNI, RTX or alkylating agents but relapsed off CNI after 3 months, or relapsed off RTX or alkylating agents after 6 months, are eligible
  • presence of active infection or a secondary cause of MN
  • diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy
  • history of resistance to CsA or other calcineurin inhibitors(CNI), RTX or alkylating agents
  • pregnancy or breast feeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).

The 2 groups in the trial

  • Rituximab monotherapyExisting treatment, for comparison

    Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.

    Treatment: Rituximab

  • Rituximab combined with cyclosporineTreatment being tested

    Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count. cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period.

    Treatment: Rituximab and cyclosporine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy
Record updated
9 December 2025